SCHEMBL1496313

SCHEMBL1496313

Cc1cc(NC(=O)c2cccnc2SCc2ccnc3ccccc23)cc(C)c1O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
HTT P42858 1/20 0.45
KDR P35968 2/20 0.45
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
LMNA P02545 1/20 0.41
ACLY P53396 1/20 0.41
MAPT P10636 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
PKM P14618 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 1/20 0.40
ATM Q13315 1/20 0.40
NR2E1 Q9Y466 1/20 0.40
PABPC1 P11940 2/20 0.40
EIF4H Q15056 2/20 0.40
BLK P51451 1/20 0.40
NR4A1 P22736 1/20 0.39
ESR2 Q92731 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1496291 0.90 KDM4E (0.47) KDM4EHTTKDRKMT2AALDH1A1
SCHEMBL1496312 0.88 KMT2A (0.47) KDM4EHTTKDRKMT2AALDH1A1
SCHEMBL1496280 0.87 KDR (0.53) KDM4EHTTKDRKMT2AALDH1A1
SCHEMBL1496320 0.86 KDR (0.43) KDM4EHTTKDRKMT2AALDH1A1
SCHEMBL1496367 0.86 KDR (0.53) KDRKMT2AALDH1A1GAALMNA
SCHEMBL1496413 0.84 KDR (0.42) KDM4EHTTKDRKMT2AALDH1A1
SCHEMBL1496305 0.83 KDR (0.50) KDRKMT2AALDH1A1GAALMNA
SCHEMBL1496366 0.83 KDR (0.66) KDM4EKDRKMT2AALDH1A1GAA
SCHEMBL1496290 0.83 NPC1 (0.55) KDRKMT2AALDH1A1LMNAACLY
SCHEMBL1496352 0.82 BLK (0.51) KDRKMT2AALDH1A1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1854787-B1 NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP SANTEN PHARMACEUTICAL CO LTD (JP) 2010-09-01 EP claimed
US-20080021064-A1 Novel cyclic compound having quinolylalkylthio group SANTEN PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 US claimed
EP-1854787-A1 NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP SANTEN PHARMACEUTICAL CO., LTD. (JP) 2007-11-14 EP claimed
US-7897774-B2 Cyclic compound having quinolylalkylthio group SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-03-01 US disclosed
EP-1854787-B1 NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP SANTEN PHARMACEUTICAL CO LTD (JP) 2010-09-01 EP disclosed
US-20080021064-A1 Novel cyclic compound having quinolylalkylthio group SANTEN PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 US disclosed
EP-1854787-A1 NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP SANTEN PHARMACEUTICAL CO., LTD. (JP) 2007-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021064-A1 Novel cyclic compound having quinolylalkylthio group SQOR, QSOX1, SQLE KDM4E 2176/4885HTT 2298/4885KDR 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.